Ibrutinib, the first small molecule of Bruton’s tyrosine kinase inhibitor (BTKi), was approved by the United States Food and Drug Administration (FDA) in November 2013 for treating recurrent mantle cell lymphoma (MCL) [1,2]. The gene discussed is IBTK; the disease is mantle cell lymphoma.